GlassScriptPhysician profile
Diego Acero
NPI 1669913133
$1,689.25
in general payments reported to CMS, 2019-2025
11 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $118 · 2024: $350 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $490 · Travel and Lodging: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.41 |
| Education | $489.83 |
| Travel and Lodging | $104.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $489.83 | 2024-2025 | Rayaldee |
| Globus Medical, INC. | $378.87 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $138.76 | 2025 | |
| Lilly USA, LLC | $135.71 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Novo Nordisk INC | $124.39 | 2024 | |
| La Jolla Pharmaceutical Company | $117.75 | 2023 | Giapreza |
| Recor Medical INC | $109.68 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ardelyx, INC. | $26.69 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $25.29 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.28 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Acero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.